◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349) Financial History

Name: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Shanghai, China with about 876 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 1349 reported CNY 686M in revenue and (CNY 157M) in net income.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China.

Interactive charts & full statements →

1349 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 686M	CNY 709M	CNY 851M	CNY 1.0B	—
Gross Profit	CNY 616M	CNY 648M	CNY 780M	CNY 947M	—
Operating Income (EBIT)	(CNY 170M)	CNY 5M	CNY 130M	CNY 124M	—
Net Income	(CNY 157M)	CNY 40M	CNY 109M	CNY 138M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1349 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 31M)	(CNY 93M)	(CNY 76M)	(CNY 71M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1349 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 2.4B	CNY 2.6B	CNY 2.9B	CNY 3.0B	—
Total Liabilities	CNY 274M	CNY 281M	CNY 518M	CNY 723M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1349 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

CURA · Curaleaf Holdings, Inc. — $3 billion
SFZN · Siegfried Holding AG — $3 billion
HIK · Hikma Pharmaceuticals PLC — $3 billion
SUPN · Supernus Pharmaceuticals, Inc. — $3 billion
AMLX · Amylyx Pharmaceuticals, Inc. — $3 billion
2552 · Hua Medicine (Shanghai) Ltd. — $3 billion
BCRX · BioCryst Pharmaceuticals, Inc. — $2 billion
RGC · Regencell Bioscience Holdings Limited — $2 billion

← 1348 All “0-9” companies 1351 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.